Richard Peterson
Follow
Get notifications in MyBN when activity occurs.
Upgrade your subscription to use this feature.
Richard Peterson
Ric Peterson has extensive experience in the dermatology industry and was chief financial officer of Dermavant Sciences where he led a diverse range of group functions including finance, company secretarial and operations. Prior to Dermavant Sciences, Mr Peterson was chief financial officer of dermatology companies Sienna Biopharmaceuticals, Novan and Medicis Pharmaceutical. At Medicis Pharmaceutical, he also held the positions of executive vice president & treasurer and played a key role in building the largest independent dermatology company and eventual sale of Medicis Pharmaceutical to Valeant for US$2.6bn in 2012.
Lists and Charts
Total Shareholder Return as at 29/11/24
| Rank | Company | 1 yr | 5 yr |
|---|---|---|---|
| 111th | Botanix Pharmaceuticals | 117% | 67% |
| 425th | RemSense Technologies | 32% | |
| 618th | Finexia Financial Group | 15% | 14% |
| 846th | EVE Health Group | 0% | -25% |
| 1656th | Peppermint Innovation | -65% | -11% |
1740 WA (and selected non WA) listed companies ranked by
1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
Revenue
| Rank | Company | Revenue | |
|---|---|---|---|
| th |  | Peppermint Innovation | $1.2m |
| 147th |  | EVE Health Group | $2.2m |
| 148th | | Botanix Pharmaceuticals | $2.1m |
| 150th | | RemSense Technologies | $1.8m |
198 listed industrial wa companies ranked by revenue.
Powered by Morningstar ®
Powered by Morningstar ®
News Articles
Related Information
Positions - Previous
| Position | Company | Year | Company's current rank |
|---|---|---|---|
| Chief Financial Officer |  | 2019 - 2020 | 148 |
| Auditor, in US | | 1992 - 1995 | 5 |
